CD8A and melanoma: Along with the in vivo evidence, FACS assays focusing on effector T cells demonstrated enhanced TILs, especially CD8+ T cells and CD4+ T cells in [212Pb]VMT01-treated melanoma tumors, indicating strong immunogenic effect of [212Pb]VMT01 α-TRT.